Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma by Fateen, Waleed et al.
© 2017 Fateen et al. This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License.  
The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, distribution, 
and reproduction in any medium, provided the original author and source are credited.
Journal of Hepatocellular Carcinoma 2017:4 123–130
Journal of Hepatocellular Carcinoma Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
123
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/JHC.S144068
Healthcare costs of transarterial 
chemoembolization in the treatment of 
hepatocellular carcinoma
Waleed Fateen1,2
Farooq Khan1
Richard J O’Neill3
Martin W James1
Stephen D Ryder1
Guruprasad P Aithal1,2
1NIHR Nottingham Biomedical 
Research Centre, Nottingham 
University Hospitals NHS Trust 
and University of Nottingham, 
2Nottingham Digestive Diseases 
Centre, University of Nottingham, 
3Department of Radiology, 
Nottingham University Hospitals, 
NHS Trust, Nottingham, UK
Background: A meta-analysis comparing drug-eluting beads transarterial chemoembolization 
(DEB-TACE) with conventional transarterial chemoembolization (cTACE) has recently been 
published. On balance, no significant differences were found in terms of objective response and 
overall survival. The impact on healthcare costs had been studied in small series based on a 
hypothetical model and was in favor of DEB-TACE. We aimed to evaluate and compare health-
care costs and effectiveness of both modalities in a cohort of patients from Nottingham, UK.
Methods: Using a dedicated radiology database, we identified all patients who had undergone 
cTACE or DEB-TACE between 2006 and 2012 at a single tertiary referral center based in 
Nottingham. We collected clinical data, including treatment response, postprocedure complica-
tions and 30-day mortality. Costing models were constructed to present both our local hospital 
perspective as well as the national health service position.
Results: During our study period, 101 procedures were performed on 43 patients (76 cTACE 
procedures on 26 patients and 25 DEB-TACE procedures on 17 patients). Overall, 11/26 in 
cTACE and 5/17 in DEB-TACE group had progressive disease (p=0.52). Adverse events were 
seen in 6/76 cTACE compared with 7/25 DEB-TACE group (p=0.16). Based on the predeter-
mined standard pathway there was an unadjusted average cost difference of £3770.30 (TACE 
=£9070.44, DEB-TACE =£5300.14) in favor of the DEB-TACE. Results from our costing models 
indicated a £2715.33 (95% CI £580.88–4849.77) cost difference in favor of the same procedure.
Conclusions: Even when the extra costs of DEB-TACE were considered, the overall treatment 
costs per patient were lower in relation to cTACE.
Keywords: hepatocellular carcinoma, transarterial chemoembolization, healthcare costs, drug-
eluting beads, objective response
Introduction
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the 
liver and the second leading cause of all cancer-related mortality globally.1,2 The 
majority of cases are diagnosed late at advanced stages and deemed unsuitable for 
curative treatments.3 Transarterial chemoembolization (TACE) is commonly used for 
the management of unresectable primary liver cancer.4 It works by blocking the tumor 
feeding arterial supply using an embolizing agent and enabling a local injection of 
chemotherapy directly into the tumor. Multiple TACE sessions may be required to 
achieve a desirable outcome.
Response to TACE is commonly judged according to time-to-event, for example, 
progression as well as overall survival.4 The Modified Response Evaluation Criteria in 
Solid Tumors (mRECIST) is commonly used to objectively measure tumor response or 
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progression. It is based on a radiological assessment of tumor 
size specifically relating to contrast enhancement.5 Sustain-
able objective response is achieved in ~35% of patients.6 
The benefits of this treatment on 2-year survival have been 
established by meta-analysis of randomized controlled trials 
(RCTs) (odds ratio, 0.54; 95% CI: 0.33, 0.89; p=0.015).7
TACE with drug-eluting beads (DEB-TACE) as opposed 
to conventional TACE (cTACE) involves the injection of 
beads into hepatic artery branches offering simultaneous 
embolization with sustained and controlled drug release. 
Consequently, DEB-TACE offers a favorable pharmaco-
kinetic profile and lower peak plasma concentrations of 
chemotherapy.8 DEB-TACE is associated with 50% 4-year 
survival based on a retrospective and non-comparative study.9
Five meta-analyses comparing the safety and efficacy of 
DEB-TACE in comparison with cTACE have been published 
within the last 2 years.10–14 The aforementioned studies had 
different selection criteria and methodologies and therefore 
report varying comparative outcomes on the safety and effi-
cacy of both procedures. Cost comparisons between cTACE 
and DEB-TACE were performed in 2 studies. Vadot et al 
retrospectively analyzed healthcare costs within the French 
infrastructure and found a significantly shorter mean hospital 
admission duration for patients who received DEB-TACE. 
This led to a subsequently better reported economic profile 
in France.15 The results of the study were limited to France 
and further studies were required to confirm generalizability 
to other national healthcare systems. Cucchetti et al con-
structed a hypothetical cost effectiveness Markov simulation 
model on published studies investigating a total number of 
1860 patients and found a lower incremental cost of DEB-
TACE.16 We have evaluated the safety, efficacy and costs of 
DEB-TACE versus cTACE from real-life patients from a 
large UK-based tertiary care institution. We aimed to first, 
validate the results published from France and review their 
generalizability. Second, validate the results published on 
a large hypothetical cohort using Markov simulation. With 
the widespread economic concerns, this may have a quick 
translation impact on healthcare systems.
Methods
Ethics and consent statement
The study is registered by the Digestive Diseases and Tho-
racic Directorate of the Nottingham University Hospitals 
NHS Trust as an audit. Ethical approval and patient consent 
were not required for this retrospective study which was 
performed as a part of our service evaluation.
Patient selection
We performed a retrospective analysis of patients who had 
cTACE or DEB-TACE between January 2006 and December 
2012 for the treatment of HCC in a tertiary referral center. 
We identified the patients using a dedicated radiology data-
base that is used to store and report procedural details as 
part of routine clinical practice. Clinical notes as well as 
electronic record information were used for data collection. 
We collected: 1) patient variables, including demographics, 
etiology of liver disease, Child–Pugh score and UK model 
for end-stage liver disease; 2) tumor variables, including 
size, location and number; 3) procedure variables, including 
number of TACE sessions required, length of hospital stay, 
postprocedure complications and 30-day mortality. Patients 
were excluded if they: 1) had not had follow-up in our unit; 
2) had TACE for indications other than HCC; 3) had both 
cTACE and DEB-TACE on different occasions. Patients were 
followed up until discharge from clinic, including death or 
until the date of the last available cross-sectional imaging, 
if still under follow-up. Computerized tomography scans 
pre- and postprocedure were used to objectively assess tumor 
response using mRECIST. The images were reviewed by an 
expert radiologist as a part of the study. Cumulative tumor 
size of the 2 largest measurable lesions per liver was used 
where there was more than 1 lesion.5
Statistical analysis
Differences between groups of continuous variables were 
assessed by unpaired t-tests (parametric data) or Mann–
Whitney U (non-parametric data) tests. A p-value <0.05 
was considered statistically significant. Possible predictors 
of objective response were fitted into a proportional ordered 
logistic regression model. This analysis was performed on 
R statistical software using R packages mass and ggplot2 (R 
core team, Vienna, Austria). TACE procedures were counted 
twice for the same patient if the interval between both pro-
cedures was more than 4 months and both were assessed 
by postprocedure cross-sectional imaging independently. 
Covariates were limited by data availability and included 
the following:
1. Interval in weeks from TACE to cross-sectional imaging
2. Tumor size at baseline
3. Vascular invasion and/or extra-hepatic disease, including 
porta-hepatis lymph nodes.
Costs
In order to obtain per patient cumulative cost figures, a refer-
ence treatment pathway was constructed with the assumption 
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that it would be followed by all patients during the study’s 
time. Follow-up procedures were modeled as shortened ver-
sions of the first procedure. Two different costing models were 
constructed in order to present both the local and the national 
perspectives. The local cost of the beads was added to both 
models since the national equivalent could not be identified. 
Details on the price weights can be found in Table 1. National 
Health Service (NHS) schedule of reference cost 2012–2013 
was used to obtain the cost data.
Cost analysis
To address the non-normality of distributions, costs were 
analyzed using generalized linear models (GLM) as described 
by Dunn et al.17 Regression on raw costs using ordinary least 
squares (OLS) was used for comparison. Covariates were 
chosen from the available dataset with the aim of  maximizing 
the model’s explanatory power. To objectively measure clini-
cal effectiveness, patient age, tumor size at presentation and 
last known mRECIST score were added to the model along 
with total costs and the treatment variable. Lowest Akaike 
information criterion and the modified Park test as described 
by Manning and Mullahy18 were used to evaluate the model’s 
goodness of fit. Three patients were excluded from the cost 
analysis due to lack of availability of sufficient data. Re-
admissions were accounted for in our cost analysis.
Results
Patient outcomes
Fifty patients in total were identified. After exclusions, we ana-
lyzed 101 procedures (cTACE=76, DEB-TACE=25) performed 
on 43 patients (cTACE=26, DEB-TACE=17) as described in 
Figure 1. Descriptive statistics are outlined in Table 2.
Table 1 Price weights of TACE-related assessments and procedures from local and national perspectives
Local price weights National average price weights
Outpatient first appointment £92 £225
Discussion at HPB MDT meeting £110 £110
CT scan with contrast £125 £106
Preoperative assessment £76 £200
Hepatobiliary interventional radiology procedure £2,596 £2,342
Outpatient follow-up appointment £76 £200
Drug-eluting beads £550 Not available
Abbreviations: CT, computerized tomography; HPB MDT, hepatobiliary multidisciplinary team; TACE, transarterial chemoembolization.
Figure 1 Summary of included and excluded patients and number of TACE procedures.
Abbreviations: cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting beads transarterial chemoembolization; TACE, transarterial 
chemoembolization.
50 patients
Patients excluded:
Patient selection
No follow-up in our centre (n=3)
Previously had both cTACE
and DEB-TACE (n=3)
Intrahepatic cholangiocarcinoma (n=1)
101 procedures,
43 patients
76 TACE procedures,
26 patients
25 DEB-TACE
procedures, 17 patients
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The majority of patients were male in both groups, with 
similar ages. Included patients had variable etiologies as 
outlined in Table 2. Both groups were followed up for more 
than 1 year on average. Patients in the DEB-TACE group 
had a significantly smaller number of nodules within their 
livers (p=0.04). Despite this, the cumulative tumor size of 
all nodules per liver added together was not significantly 
different between both groups. DEB-TACE group required 
significantly less sessions (median=1) in comparison with 
cTACE (median=2.5) per patient (p<0.005).
Mortality and complications
One patient in the DEB-TACE group died from biliary sepsis 
on day 14 of the same admission. In the cTACE group, there 
was a single 30-day mortality from hepatic decompensation; 
on day 2, postprocedure, the patient was transferred to a 
specialist palliative care facility. Severe transaminitis (>20× 
the normal) and hospital-acquired pneumonia occurred post-
procedure in 1 patient in the cTACE group which prolonged 
admission in hospital by 5 days. One of the DEB-TACE cases 
had re-admission 6 days after the discharge from hospital 
with left hepatic artery dissection complicated by hospital-
acquired pneumonia. The second admission had a duration 
of 7 days. There were no other notable severe complications 
otherwise, apart from limited transaminitis and postemboliza-
tion syndrome (e.g., fever, nausea, vomiting or pain).
Objective response
The method of TACE delivery (cTACE vs DEB-TACE) was 
not found to be independent predictor of objective response. 
Tumor size predicted objective response independent of 
all other variables as demonstrated in Figure 2 (p=0.0004, 
OR=1.035, 95% CI 1.017–1.057).
Costs
The analysis of the cost data took into account 40 out of the 43 
patients for whom there was a complete dataset. The cTACE 
and DEB-TACE arms differed in the added cost of the beads 
for the DEB-TACE and the average number of follow-up 
procedures per patient. Using the aforementioned pathway, 
the 2 procedures had an unadjusted average cost difference of 
£3770.30 (cTACE=£9070.44, DEB-TACE=£5300.14) based 
on the NHS costing and of £3253.68 (cTACE=£9033.19, 
DEB-TACE=£5222.89) based on local costing, in favor of 
the DEB-TACE arm. Results are summarized in Table S1. 
Upon comparing the output of both models, there was no 
significant benefit from the use of GLMs while the Park 
test did not highlight a specific model as the best fit. On the 
OLS regression model, the cost difference was at £2715.33 
based on the national NHS costing and at £2746.58 based on 
our local costing. Treatment type was found to predict total 
costs independent of all other included covariates (p=0.014).
Discussion and conclusions
We have demonstrated that overall treatment costs of DEB-
TACE are lower than that of cTACE for the treatment of HCC. 
Our analysis is based on a real-life scenario. In the UK, all 
patients with HCC are managed through a regional cancer 
network with treatment decisions made by multidisciplinary 
teams (MDTs) based on predetermined pathways. Our 
economic model was based on the predetermined standard 
pathway which included the patient’s journey from time of 
referral to the tertiary center until the time of discharge, 
death or last follow-up. It included the costs of outpatient 
appointments, MDT discussion, inpatient stay, blood tests, 
Table 2 Descriptive statistics of included patients in both groups
DEB-TACE cTACE p-value
Number of patients 17 26
Number of procedures 25 76
Age, years (mean ± SEM) 67.76±3.05 68.35±2.42 0.88
Gender
Male 14 24
Female 3 2
Etiology
Unknown/noncirrhotic 5 10
ALD 7 4
HCV 2 3
HBV 1 4
NASH 2 3
Other 0 2
Number of tumors
Multifocal 2 12
Two lesions 1 6 0.04
Single lesion 14 8
Size of tumor in mm (mean ± 
SEM)
55.35±7.44 75.85±7.25 0.065
Procedure per patient (mean 
± SEM)
1.43±0.16 3.03±0.33 0.0007
Follow-up in months 12.8 17.6 0.13
Disease response (%) mRECIST
SD (%) 10 20
PD (%) 30 40
PR (%) 15 30
CR (%) 45 10
Inpatient stay, days (mean ± SEM) 2.81±0.5 2.37±0.11 0.21
Complications 7/25 6/76 0.16
30-day mortality 1 1
Abbreviations: ALD, alcohol related liver disease; CR, complete response; 
cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting 
beads transarterial chemoembolization; HBV, hepatitis B virus; HCV, hepatitis C 
virus; mRECIST, Modified Response Evaluation Criteria In Solid Tumors; NASH, 
nonalcoholic steatohepatitis; PD, progressive disease; PR, partial response; SD, 
stable disease; SEM, standard error of mean.
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TACE procedure and cross-sectional imaging. This economic 
modeling has shown an unadjusted average cost benefit of 
£3770.30 for patients receiving DEB-TACE compared with 
those who received cTACE. Patients undergoing DEB-TACE 
have required less number of procedures over the observed 
study period. The data suggest that contribution to the cost 
comparison is in favor of DEB-TACE with potential benefits 
to healthcare costs. Although neither the OLS regression nor 
any GLM had a significant explanatory power, there is an 
indication that the DEB-TACE arm can be less costly in the 
medium term. This is consistent with recently published data 
by French and Italian groups.15,16
Our limitations include the retrospective study design and 
possible selection bias, including the fact that patients treated 
by DEB-TACE had significantly fewer target liver lesions. 
The cost of beads reported in our study may lack generaliz-
ability as our analysis was based on our local purchase costs. 
However, the commissioning of health services is determined 
based on these estimates; so, these influence the design and 
delivery of services in the British NHS. The use of cTACE 
had been well established in our unit for many years. In 
contrast, DEB-TACE had been introduced as a relatively 
new technique. The choice of patients having DEB-TACE 
was mainly influenced by the time of introduction of the 
new service rather than specific clinical features. Similarly, 
classically, we will protocol cross-sectional imaging after 2 
sessions of cTACE. However, as DEB-TACE was relatively 
new at the time of introduction, we protocoled cross-sectional 
imaging after each session of DEB-TACE in the majority of 
cases. Cross-sectional imaging after each session of cTACE 
may have led to different results. The study also highlights 
that, judging by objective response, we demonstrated that 
DEB-TACE is similar to cTACE. It also affirms the likelihood 
that its medico-economic consequences are more favorable 
in the medium term in comparison with cTACE.
There is some controversy in the literature, however, about 
the effect of DEB-TACE on objective tumor shrinkage.19 We 
therefore fitted our data into a logistic regression model and 
confirmed lack of direct effect from DEB-TACE on improved 
objective tumor response within our cohort. We found tumor 
size to be an independent predictor of objective response to 
TACE as would be expected. Interestingly, progressive dis-
ease (PD) did not seem to be limited by tumor size, that is, 
patients who had PD did not necessarily have larger tumors 
(Figure 2). This highlights the seemingly unstoppable role of 
tumor biology in dictating behavior and prognosis.
Figure 2 The target lesions treated by DEB-TACE (A - red) and cTACE (B - blue) are demonstrated.
Notes: The figure shows objective responses in relation to tumor size as achieved by both modalities of TACE. Both modalities showed worse objective responses as the 
tumor size got bigger. PD outcome clearly did not follow the same trend. The width of each bar is proportional to sample size.
Abbreviations: CR, complete response; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting beads transarterial chemoembolization; PD, 
progressive disease; PR, partial response; SD, stable disease.
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Based on the recent meta-analyses, DEB-TACE has no 
statistically significant impact on survival or objectively eval-
uated treatment response according to RCTs. In contrast, the 
largest meta-analysis to date that included non-RCT prospec-
tive and retrospective studies, demonstrated that DEB-TACE 
was associated with survival benefit.13 Another large meta-
analysis including 4 RCTs and 6 retrospective studies found 
significant differences in the incidence of post-embolization 
syndrome or liver dysfunction (Table 3).14 Meta-analysis 
limited to RCTs found DEB-TACE to be safer, specifically in 
terms of myelosuppression and alopecia.11 Xie et al, reported 
significant improvement in objective response in the DEB-
TACE group. The meta-analysis was subsequently heavily 
criticized by Kodama et al who reported no difference in 
objective response upon reproducing the results.12,19
It is worth noting that there are several limitations of 
reviewing studies based on meta-analysis. First, the number 
of TACE sessions required and practically performed was 
not compared. The studies did not report if less sessions were 
required by DEB-TACE to achieve the same outcome. Second, 
the size of beads and dosage of chemotherapy was variable. 
Third, the timing and criteria used for radiological assess-
ments were heterogeneous. Finally, the patient populations, 
for example, model for end-stage liver disease score and stage 
of fibrosis was not unified. Better efficacy and safety remain 
a theoretical possibility based on the aforementioned results.
We conclude that DEB-TACE, a newer technique for 
the treatment of unresectable HCC, is an effective modality 
and our cost analysis shows it to have cost benefits when 
compared with cTACE. Prospective head-to-head trials on 
selected patient populations are needed to evaluate its efficacy 
as well as cost benefits to the healthcare system. 
Data sharing statement
The dataset is available from the corresponding author at 
(Guru.Aithal@nuh.nhs.uk). Consent was not obtained from 
Table 3 Recently published meta-analysis comparing DEB-TACE to cTACE
Citation Total studies Study design Patients Surv OR AE
Zhou et al (2014)10 9 5 RCTs
3 retrospective
830 Better Better Same
Xie et al (2015)12 6 4 RCTs
0 retrospective
652 Same Better Same
Hui et al (2015)11 4 4 RCTs 527 NA Same Better
Facciorusso et al (2016)14 12 4 RCTs 
6 retrospective
1449 Same Same Same
Chen et al (2017)13 16 4 RCTs
9 retrospective
1832 Better Same Same
Abbreviations: AE adverse events; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting beads transarterial chemoembolization; NA, not 
available; OR, objective response; RCTs, randomized controlled trials; Surv, survival.
participants but the presented data are anonymized and risk 
of identification is low.
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Table S1 Cost models: (goodness of fit and ordinary least squares [robust])
Regression models Incremental effect on cost 95% CI max 95% CI min AIC
Local costings
OLS (robust)
−£2,746.58 −£4,899.02 −£594.14 19.39
GLM (Gaussian-Log)
−£3,291.65 −£4,952.08 −£2,104.93 19.36
GLM (Gamma-ID)
−£2,589.00 −£4,676.21 −£501.80 20.19
GLM (Gamma-Log)
−£2,824.93 −£5,266.25 −£2,153.15 20.20
GLM (Inverse Gaussian-ID)
−£2,671.19 −£4,531.63 −£810.75 28.69
GLM (Inverse Gaussian-Log)
−£3,196.00 −£20,881.79 −£2,109.59 28.69
GLM (Poisson-ID)
−£2,609.35 −£2,667.73 −£2,550.97 1243.50
GLM (Poisson-Log)
−£2,970.33 −£4,794.18 −£2,083.05 1232.81
National NHS costing
OLS (robust)
−£2,715.33 −£4,849.77 −£580.88 19.37
GLM (Gaussian-Log)
−£3,244.57 −£4,865.83 −£2,093.79 19.35
GLM (Gamma-ID)
−£2,557.90 −£4,635.49 −£480.31 20.21
GLM (Gamma-Log)
−£2,790.23 −£5,155.18 −£2,134.29 20.21
GLM (Inverse Gaussian-ID)
−£2,631.80 −£4,480.63 −£782.97 28.72
GLM (Inverse Gaussian-Log)
−£3,051.61 −£16,820.11 −£2,118.51 28.72
GLM (Poisson-ID)
−£2,580.16 −£2,638.81 −£2,521.51 1214.53
GLM (Poisson-Log)
−£2,933.00 −£4,712.09 −£2,069.84 1204.22
Abbreviations: AIC, Akaike information criterion; GLM, generalized linear model; NHS, National Health Service; OLS, ordinary least squares.
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